Table 2 Baseline characteristics of the biologic-experienced population
Biologic -Experienced | ||||||
|---|---|---|---|---|---|---|
PS-Matched | PS-Trimmed | |||||
At time of initiation | Abatacept N = 92 | TNF N = 92 | Standardized Difference | Abatacept N = 145 | TNF N = 129 | Standardized Difference |
Age (years), Mean (SD) | 56.2 (12.5) | 56.8 (12.2) | 0.05 | 56.0 (12.6) | 56.5 (12.4) | 0.04 |
Female, n (%) | 65 (70.7) | 67 (72.8) | 0.05 | 107 (73.8) | 87 (67.4) | 0.14 |
White, n (%) | 89 (98.9) | 82 (90.1) | 0.39 | 142 (99.3) | 117 (92.9) | 0.34 |
Medicaid, n (%) | 8 (8.70) | 7 (7.6) | 0.04 | 14 (9.7) | 9 (7.0) | 0.10 |
Full/Part time work, n (%) | 47 (51.1) | 49 (53.3) | 0.04 | 78 (53.8) | 65 (50.4) | 0.07 |
Retired, n (%) | 19 (20.7) | 20 (21.7) | 0.03 | 24 (16.6) | 32 (24.8) | 0.20 |
Disabled, n (%) | 15 (16.3) | 18 (19.6) | 0.08 | 31 (21.4) | 23 (17.8) | 0.09 |
Never smoker, n (%) | 34 (37.0) | 34 (37.0) | 0.00 | 59 (40.7) | 50 (38.8) | 0.04 |
Former smoker, n (%) | 33 (35.9) | 30 (32.6) | 0.07 | 46 (31.7) | 46 (35.7) | 0.08 |
Current smoker, n (%) | 25 (27.2) | 28 (30.4) | 0.07 | 40 (27.6) | 33 (25.6) | 0.05 |
BMI, Obese (≥ 30), n (%) | 35 (38.0) | 31 (33.7) | 0.09 | 57 (39.3) | 50 (38.8) | 0.01 |
Hypertension, n (%) | 30 (32.6) | 32 (34.8) | 0.05 | 50 (34.5) | 41 (31.8) | 0.06 |
Serious Infections, n (%) | 6 (6.5) | 6 (6.5) | 0.00 | 11 (7.6) | 7 (5.4) | 0.09 |
Cardiovascular, n (%) | 15 (16.3) | 13 (14.1) | 0.06 | 22 (15.2) | 17 (13.2) | 0.06 |
Duration of RA years, Mean (SD) | 11.1 (10.3) | 11.5 (10.4) | 0.03 | 11.9 (9.9) | 10.9 (10.6) | 0.10 |
CDAI, Mean (SD) | 27.6 (13.0) | 27.4 (12.1) | 0.02 | 28.2 (12.3) | 27.7 (12.4) | 0.04 |
TJC(28), Mean (SD) | 9.8 (6.6) | 9.4 (7.1) | 0.05 | 10.2 (6.5) | 9.7 (7.2) | 0.07 |
SJC(28), Mean (SD) | 7.7 (5.6) | 7.7 (4.6) | 0.00 | 7.8 (5.6) | 8.0 (5.2) | 0.04 |
CRP, Mean (SD) | 10.3 (14.8) | 9.2 (14.1) | 0.07 | 9.7 (14.4) | 10.2 (15.3) | 0.04 |
DAS28-CRP, Mean (SD) | 4.7 (1.2) | 4.6 (1.1) | 0.06 | 4.7 (1.1) | 4.6 (1.0) | 0.09 |
RF, Mean (SD) | 210.7 (258.0) | 163.0 (244.4) | 0.19 | 195.9 (245.4) | 175.5 (236.7) | 0.08 |
RF+, n (%) | 85 (92.4) | 81 (88.0) | 0.15 | 135 (93.1) | 113 (87.6) | 0.19 |
mHAQ, Mean (SD) | 0.5 (0.5) | 0.5 (0.5) | 0.00 | 0.6 (0.5) | 0.5 (0.5) | 0.10 |
PGA (VAS 0-100), | ||||||
Mean (SD) | 49.9 (21.7) | 51.2 (17.5) | 0.07 | 48.7 (19.8) | 50.5 (19.2) | 0.10 |
PtGA (VAS 0-100), | ||||||
PGA, Mean (SD) | 51.4 (24.1) | 50.8 (23.6) | 0.03 | 53.4 (24.4) | 49.4 (24.5) | 0.16 |
Pain (VAS 0-100), | ||||||
Mean (SD) | 53.2 (25.0) | 52.5 (27.1) | 0.03 | 56.0 (25.1) | 51.2 (28.3) | 0.18 |
Fatigue (VAS 0-100), | ||||||
Mean (SD) | 56.0 (28.7) | 53.5 (29.0) | 0.09 | 57.6 (27.6) | 52.2 (28.9) | 0.19 |
Prior csDMARD usage count, | ||||||
Mean (SD) | 1.2 (1.2) | 1.3 (1.3) | 0.09 | 1.4 (1.3) | 1.2 (1.2) | 0.18 |
Prior TNFi usage count, n | 92 | 92 | 145 | 129 | ||
0, n (%) | 1 (1.1) | 2 (2.2) | 0.09 | 1 (0.7) | 3 (2.3) | 0.13 |
1, n (%) | 53 (57.6) | 50 (54.4) | 0.07 | 60 (41.4) | 84 (65.1) | 0.49 |
2+, n (%) | 38 (41.3) | 40 (43.5) | 0.04 | 84 (57.9) | 42 (32.6) | 0.53 |
Prior non-TNFi usage count, n | 92 | 92 | 145 | 129 | ||
0, n (%) | 80 (87.0) | 86 (93.5) | 0.22 | 123 (84.8) | 120 (93.0) | 0.26 |
1, n (%) | 10 (10.9) | 6 (6.5) | 0.15 | 18 (12.4) | 9 (7.0) | 0.18 |
2+, n (%) | 2 (2.2) | 0 (0.0) | 0.21 | 4 (2.8) | 0 (0.0) | 0.24 |
Prior biologic usage count, n | 92 | 92 | 145 | 129 | ||
0, n (%) | 0 (0.0) | 0 (0.0) | N/A | 0 (0.0) | 0 (0.0) | N/A |
1, n (%) | 49 (53.3) | 49 (53.3) | 0.00 | 54 (37.2) | 83 (64.3) | 0.56 |
2, n (%) | 28 (30.4) | 37 (40.2) | 0.20 | 57 (39.3) | 38 (29.5) | 0.21 |
3+, n (%) | 15 (16.3) | 6 (6.5) | 0.31 | 34 (23.5) | 8 (6.2) | 0.50 |
Current MTX use, n | 92 | 92 | 145 | 129 | ||
Yes, n (%) | 43 (46.7) | 44 (47.8) | 0.02 | 72 (49.7) | 64 (49.6) | 0.00 |
Current Prednisone use, n | 92 | 92 | 145 | 129 | ||
Yes, n (%) | 43 (46.7) | 37 (40.2) | 0.13 | 64 (44.1) | 55 (42.6) | 0.03 |